Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Intrinsic apoptotic pathway proteins are a collective group of molecules that regulate and execute mitochondria-mediated apoptosis in response to cellular signals such as DNA damage, hypoxia, or oncogene activation. Key regulators include members of the Bcl-2 family (pro-apoptotic: BAX, BAK, BAD, BOK; anti-apoptotic: Bcl-2, Bcl-xL, Mcl-1), cytosolic proteins like Apaf-1, mitochondrial proteins such as cytochrome c, and executioner enzymes known as caspases (initiator caspase-9, effector caspase-3, caspase-7). Inhibitors of apoptosis (IAPs; e.g., XIAP, survivin) regulate caspase activity. The pathway is essential for normal development, tissue homeostasis, and elimination of damaged cells, with dysregulation linked to cancer, neurodegeneration, and other diseases. Individual proteins often serve as both biomarkers and therapeutic targets.
Bcl-2 inhibition increases mitochondrial permeability, triggers cytochrome c release; SMAC mimetics antagonize IAPs, allowing caspase activation; Caspase activation cleaves cellular substrates leading to apoptosis
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Intrinsic apoptotic pathway proteins.